Results 291 to 300 of about 7,525,117 (401)

Life Insurance and the Presumption of Death [PDF]

, 1937

core   +1 more source

The integration of the British Pharmacological Society's prescription safety assessment into the WHO 6‐step model of rational pharmacotherapy in a Turkish medical school

British Journal of Clinical Pharmacology, EarlyView.
Aims At Koç University School of Medicine, a one‐week rational pharmacotherapy (RPHM) programme, modelled after WHO 6‐step, has been introduced in the fourth‐year curriculum to improve prescription skills. For efficient problem‐based learning (PBL) sessions on a prespecified topic, students need to brush up on basic pharmacology knowledge, so we ...
Sinem Ezgi Gülmez, Gülnihal Özcan, Hakan S. Orer   +2 more
wiley   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

The TENMYO: The Character of the Women Insured of Life Insurance

, 1963
Seitaro Kikuchi, Susumu OBARA, Akira AMAGI, Hiroshi NAGOSHI, Susumu Sasaki, Kazomi TENMYO   +5 more
openalex   +2 more sources

Mild psoriasis as a suitable model for proof‐of‐mechanism in a phase 1B setting: Results from a double‐blind placebo‐controlled trial with guselkumab

British Journal of Clinical Pharmacology, EarlyView.
Aims Early clinical development of novel psoriasis therapies is hampered by a decreasing number of moderate‐to‐severe psoriasis patients eligible for participation in trials since efficacious treatments, such as biologics, have become widely available.
Jannik Rousel, Menthe E. Bergmans, Lisa J. Bruijnincx, Sissi Lin, Tessa Niemeyer‐van der Kolk, Roman Bohoslavsky, Yalçin Yavuz, Naomi B. Klarenbeek, Joke A. Bouwstra, Robert Rissmann, Martijn B. A. van Doorn, the Next‐Generation ImmunoDermatology Consortium (NGID)   +11 more
wiley   +1 more source

Cardiac, Vascular and Renal Diseases from the Viewpoint of Life Insurance Medicine

, 1962
Takaaki Issiki
openalex   +2 more sources

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Financing the Natural Gas Industry: The Role of Life Insurance Investment Policies

, 1962
Lawrence L. Crum, Richard Hooley
openalex   +2 more sources

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

Valuation of Securities Holdings of Life Insurance Companies.

, 1963
Haughton Bell, Harold G. Fraine
openalex   +2 more sources